Technical Analysis for CYCC - Cyclacel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 2.51 3.29% 0.08
CYCC closed up 3.29 percent on Monday, March 18, 2024, on 11 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Mar 19
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Flat

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Gapped Up Strength 0.00%
Fell Below 50 DMA Bearish 3.29%
Bollinger Band Squeeze Range Contraction 3.29%
50 DMA Support Bullish 0.56%
Bollinger Band Squeeze Range Contraction 0.56%
20 DMA Resistance Bearish -3.09%
Crossed Above 50 DMA Bullish -3.09%
Bollinger Band Squeeze Range Contraction -3.09%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 11 hours ago
Possible Inside Day about 11 hours ago
60 Minute Opening Range Breakout about 13 hours ago
Gap Up Closed about 15 hours ago
Gap Up Partially Closed about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cyclacel Pharmaceuticals, Inc. Description

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Inflammatory Diseases Cancer Cell Autoimmune And Inflammatory Disease Cyclacel Cell Cycle Cyclin Dependent Kinase Dna Synthesis Human Cancers PLK1 Cdk Inhibitor Cell Cycle Checkpoint Cyclin Dependent Kinase 2 Sapacitabine Seliciclib

Is CYCC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.2
52 Week Low 2.0
Average Volume 176,787
200-Day Moving Average 5.87
50-Day Moving Average 2.50
20-Day Moving Average 2.62
10-Day Moving Average 2.51
Average True Range 0.24
RSI (14) 48.19
ADX 17.01
+DI 19.11
-DI 16.58
Chandelier Exit (Long, 3 ATRs) 2.37
Chandelier Exit (Short, 3 ATRs) 3.01
Upper Bollinger Bands 2.91
Lower Bollinger Band 2.33
Percent B (%b) 0.31
BandWidth 21.99
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0151
Fundamentals Value
Market Cap 2.66 Million
Num Shares 1.06 Million
EPS -29.85
Price-to-Earnings (P/E) Ratio -0.08
Price-to-Sales 6.32
Price-to-Book 0.56
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.80
Resistance 3 (R3) 2.79 2.69 2.75
Resistance 2 (R2) 2.69 2.62 2.69 2.73
Resistance 1 (R1) 2.60 2.57 2.65 2.61 2.72
Pivot Point 2.50 2.50 2.52 2.50 2.50
Support 1 (S1) 2.41 2.43 2.46 2.42 2.30
Support 2 (S2) 2.31 2.38 2.31 2.29
Support 3 (S3) 2.22 2.31 2.27
Support 4 (S4) 2.23